Tag: Crixivan

Approved by the FDA in 1996, Crixivan (indinavir) was a landmark protease inhibitor in the fight against HIV, but its mechanism is key to understanding how does Crixivan work to halt viral replication. It was one of the first highly effective drugs to transform HIV from a rapidly fatal illness into a manageable chronic condition, ushering in the era of highly active antiretroviral therapy (HAART).

First approved in 1996 as a breakthrough in HIV treatment, Crixivan (indinavir) was a landmark medication; however, today, **is CRIXIVAN still used** in clinical practice? The answer is no, as it has been largely discontinued due to significant side effects, complex dosing requirements, and the advent of superior, more tolerable treatments.

Approved by the FDA in 1996, CRIXIVAN represented a major advancement in HIV/AIDS treatment as one of the first protease inhibitors. The action of CRIXIVAN, whose generic name is indinavir, is to target a critical enzyme necessary for the virus's life cycle. It played a crucial role in the development of highly active antiretroviral therapy (HAART).